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We assessed horizontal gene transfer between bacteria in the gastrointestinal (GI) tract. During the last decades, the emergence
of antibiotic resistant strains and treatment failures of bacterial infections have increased the public awareness of antibiotic
usage. The use of broad spectrum antibiotics creates a selective pressure on the bacterial ﬂora, thus increasing the emergence
of multiresistant bacteria, which results in a vicious circle of treatments and emergence of new antibiotic resistant bacteria. The
human gastrointestinal tract is a massive reservoir of bacteria with a potential for both receiving and transferring antibiotic
resistance genes. The increased use of fermented food products and probiotics, as food supplements and health promoting
products containing massive amounts of bacteria acting as either donors and/or recipients of antibiotic resistance genes in the
human GI tract, also contributes to the emergence of antibiotic resistant strains. This paper deals with the assessment of antibiotic
resistance gene transfer occurring in the gut.
1. Emergence of AntibioticResistance
The introduction of antibiotics after World War I resulted in
a dramatic decrease of numbers of deaths due to bacterial
infections. Today, antibiotics have lost their status as the
“miracle drug” [1, 2] and “treatment failure” is a new
and often seen situation [1–5]. The increase of antibiotic
resistance is to be blamed for this medical emergency.
The sustainability of antibiotic resistance is partly due to
selection of already resistant bacteria that become the new
dominant population in the environment. Furthermore,
antibiotic usage urges bacteria sensitive to antibiotics to
become resistant in order to survive. Survival mechanisms
include the acquisition of antibiotic resistance genes from
other bacteria/phages (horizontal gene transfer or trans-
duction), mutations in speciﬁc genes, and alteration of the
bacterial surface. Thus continuous usage and accumulation
of antibiotics in the environment has resulted in the increase
of antibiotic resistant bacteria not only in Europe but
also worldwide. The relationship between antibiotics used
as antimicrobial growth promoters (AGPs) in production
animals and the development of resistant bacteria in food
products has been related to human food born infections
with resistant strains. This was not easy to acknowledge.
A few countries within the European Union (EU) have
acted on the new research regarding the suspicious use of
AGP [6]. These countries were Sweden in 1986, Norway
in 1995, and Denmark in 1998-1999 [7, 8]. Despite a
signiﬁcant decrease in bacterial antibiotic resistance levels
in the countries banning growth promoter products, four
diﬀerent AGPs were in use till January 2006, at which point
the EU commission initiated the ban of all AGP [9].
Numerous factors inﬂuence the development of antibi-
otic resistance misuse being the obvious factor. The use of
antibiotics is inﬂuenced by level of knowledge, expectations,
choice of prescription, patient behaviour, economics and
health system [10]. Patient-related factors often include
inappropriate antibiotic use, like self-medication or inad-
equate doses despite the prescription text. The prevalence
of self-medication in Europe was investigated in 2006 [11].
It was concluded that the levels of self-medication were
higher in Eastern and Southern Europe than in Northern
and Western Europe. Similarly, Northern countries as well
as the Netherlands had the lowest frequency of antibiotic
consumption and the lowest level of resistant bacteria [11,
12]. The prescription system for drugs is also important.
In developing countries, antibiotics can be purchased in
single doses, which increase the risk of the antibiotic2 International Journal of Microbiology
treatment being terminated before clinical success. In some
countries, antibiotics can be purchased over the counter and
prescription is not even necessary, which will also contribute
to the rate of incomplete treatments and self-medication.
Advertising by television, radio, print media, or internet
allows pharmaceutical companies to target a speciﬁc brand
toward physicians as well as the general public. All of the
above-mentioned factors can contribute to a rise in the resis-
tance level [11]. However, further development of antibiotic
resistance might be avoided by acquiring knowledge on the
mechanisms of bacterial antibiotic resistance. Furthermore,
regulatory agencies can set up guidelines and measures,
in order to use antibiotics adequately. For example, some
countries found that advertising against inappropriate use
of antibiotics in national campaigns can reduce the total
amount used due to awareness and proper information of
the public [13]. During the last decades, there has been an
increased focus on persistent bacterial bioﬁlm formation on
medical devices, implants, and environmental bioﬁlms [14,
15]. Interestingly, it has been shown that bioﬁlms were hot
spot for horizontal gene transfer [16–18]. Thus, promoting
development of antibiotic resistance in bacteria.
Changes in living standards have resulted in a large,
ageing human population, and in increased usage of antibi-
otics. Intensive and long-term hospitalisations due to new
advancesinmedicineoftenresultinnewinfections(hospital-
acquired infections) that are expensive to control and
diﬃcult to eradicate. These occur worldwide due to failures
in simple infection control, such as inadequate hand hygiene
and changing of gloves [19]. Increased usage of broad
spectrum antibiotics in order to avoid treatment failure
created a vicious circle in the hospitals, as the use of broad
spectrum antibiotics inﬂuenced the level of multiresistant
bacteria and their presence [20].
2. The GastrointestinalTractas
a Reservoir of AntibioticResistance Genes:
Recipients or Donors
The human intestine is a complex ecosystem with a large
species diversity, of at least 400 diﬀerent bacterial species
[21, 22]. The density varies through the diﬀerent parts of
the GI tract from 104 bacteria/mL in the stomach to 1012
bacteria/g faeces in the distal part of the colon [23, 24].
By classical culture techniques approximately 5–15% of the
species present in the GI tract are detected [25]. New
estimates by metagenomic approaches of the bacterial ﬂora
have suggested that the presence of bacterial species might be
as high as 1150 [26]. Despite attempts to stop the antibiotic
resistance development, the level of resistant bacteria is on
theriseandthehypothesisthatourGItractactsasareservoir
of antibiotic resistance genes is widely accepted [27]. “Could
the microﬂora of the human colon, normally considered
innocuous or beneﬁcial, be playing a more sinister role in
human health as a reservoir for antibiotic resistance genes?”
was the hypothesis set by Salyers and coworkers [28].
Furthermore, it is known that genes responsible for
antibiotic resistance are present in microorganisms, provid-
ing them with self-protection to the antibiotic compounds
they produce as defence mechanism against other microor-
ganisms. Similarities among the genes and resistance mech-
anisms found in the antibiotic producers and in the human
pathogenic bacteria suggest that the producer bacteria are
the pool of origin of antibiotic resistance genes [29, 30].
During antibiotic treatment, all bacteria in the human/
animal body are exposed to selective pressure of the
antibiotic. Consequently, the GI is highly exposed, especially
during oral therapy. This results in the selection of naturally
resistant strains carrying an important genetic pool that
might be capable of transferring antibiotic resistance genes
to other strains present in the human intestine. Moreover,
resistant food contaminants that originate from animals
and are consumed by humans, can also act as a gene pool
(donors) of antibiotic resistance genes [31].
In general, becoming resistance towards antibiotics has
been associated with a biological ﬁtness cost. The cost
weakensthebacteria’sabilitytomultiplyandsurvivewithina
host [32]. The connection between resistance and decreased
ﬁtness has stimulated the idea that a reduction in the use
of antibiotics would lead to a reduction in the frequency
of resistant bacteria through natural selection [33]. Further-
more, cross-resistance is of importance. Both in vitro and in
vivo studies have illustrated that “compensatory evolution
can stabilise resistant bacterial populations in the absence
of antibiotics by making them as ﬁt as susceptible clones”
[33]. In addition, resistant bacteria can alleviate the cost
of resistance by acquiring additional ﬁtness-compensatory
mutations [34–36]. The importance of environmental con-
ditions aﬀecting the ﬁtness costs was also shown [37, 38].
Mutations that have occurred in clinical isolates are seen to
compensate for ﬁtness cost in order to stabilise the resistant
pathogens in the population [29, 39]. Still, this reversibility
in clinical settings is expected to be slow or nonexistent [33].
Resistance genes from both Gram-positive and Gram-
negative pathogenic bacteria have revealed almost identical
sequences, suggesting that transfer of antibiotic resistance
genes across genera has occurred. Furthermore, it is sug-
gested that transfer events have occurred recently and are
evolutionary recent events due to high sequence identity
[29].Itisalsosuggestedthatageneﬂuxoccursinnaturefrom
Gram-positive cocci, (Enterococci/Streptococci) to Gram-
negative bacteria [29] with genes coding for streptogramins
being described as examples [29].
3. Effect of Antibiotics to the
GastrointestinalFlora
The physiological eﬀect of the bacterial ﬂora of the GI
tract is described as “Fermentation of non-digestible dietary
residues and endogenous mucus: salvage of energy as short-
chain fatty acids, production of vitamin K, absorption of
ions; control of epithelial cell proliferation and diﬀerentia-
tion; development and homoeostasis of the immune system
andprotection againstpathogens (thebarrier eﬀect)”[40].A
symbioticrelationbetweenthebacteriaandthehostprovides
thehostwithoptimalprotection.Thehostprovidesnutrients
to bacteria and bacteria repay by providing a colonisation
barrier [40].International Journal of Microbiology 3
When using antibiotics as infection treatment, a distur-
bance in the ﬂora of the GI tract is created. The barrier
is broken and potentially pathogenic bacteria are allowed
to colonise the intestine [40]. Disturbances of the normal
GI ﬂora are also seen after radical changes of the host diet
or after radiation treatments [41]. The eﬀect of diﬀerent
antibiotics on the indigenous ﬂora was investigated and it
was found that clindamycin, erythromycin, cefoperazone,
ceftriaxone, and moxalactam have a pronounced inﬂuence
on the ﬂora [41, 42]. The most common complication of
antibiotic treatment is excess colonisation of the gut by
Clostridium diﬁcile, resulting in severe and sometimes fatal
enteric diseases [43, 44].
Furthermore,antibioticscreateaselectivepressureonthe
intestinal ﬂora, risking overgrowth of resistance strains [40].
This, in turn, increases the threat of antibiotic resistant gene
transferamong the indigenous ﬂora and, at worst,transferto
other pathogenic bacteria. The risk of developing antibiotic
resistant strains which can be transmitted by patient-to-
patient contact and the spreading of resistance genes can be
diminished by choosing antibiotics with a minimum eﬀect
on the GI ﬂora [41].
4. Model Systems for Studying the
Development ofAntibiotic Resistanceinthe
GastrointestinalTract
In order to assess the eﬀect of antibiotics on the gastroin-
testinal ﬂora, a number of models have been developed, both
in in vitro models, where a number of conditions can be
controlled as well as in vivo animal models, resembling the
human/animal host.
In vitro conjugation is conducted in liquid media, on
agar plates or on ﬁlters placed on agar plates. These are
often the ﬁrst experiments by which frequency of transfer
can be observed, since all the parameters can be controlled,
that is, growth media, temperature, conjugation time,
selective pressure, and so forth. In vitro systems trying to
mimic the GI tract have been successfully used, such as
batch fermentors and continuous ﬂow fermentors, to study
the eﬀects of pH on the degradation of nutrients, CO2
production among others [45].
Diﬀerent in vivo models were used to conﬁrm in vitro
results, and to mimic the complexity of the host environ-
ment. These included alfalfa sprouts as a plant model, and
a rumen model, and animal models. [46]. Most experiments
related to pathogenic bacteria and their frequency of in vivo
gene transfer have been conducted in rodents (especially
mice). Rodents are often preferred due to high reproduction,
shortgestation,aminimumofhusbandry,andlowcosts.The
histological structure of the GI tract has similarities to the
human gut, including epithelial layers and mucous secretion
[47]. Eﬀect of bacterial colonisation of the gut, including
gene transfer, expression of virulence characteristics, and
spatial distribution have therefore been investigated in mice.
Since the gut has natural resistance (barrier eﬀect) to
colonization by foreign bacterial strains, the experiments
are often performed in germ-free and/or antibiotic-treated
rodents. Germ-free animals are usually inoculated only with
the two strains of interest (donor and recipient strains),
thus it is called a diassociated model. The model is a highly
controlled setup where only few factors in the GI tract
vary. However, a very important factor is that the rodents
are coprophages (ingest faeces) which leads to uncontrolled
reinoculation. This can be decreased by using gratings and
individual cages. The model allows the inoculated bacteria to
colonise the GI tract in very high numbers: 109-1010 CFU/g
faeces. Bacteria which are normally transient in conventional
animals will now colonise the GI tract in high numbers due
to lack of competition from the indigenous ﬂora [48]. High
numbers of the two strains increase the chance of cell-to-
cell contact and, therefore, increase the opportunity of gene
transfer. Thus, the diassociated model is often described as a
worst case scenario model. An investigation of the germ-free
mice has revealed that the lymph nodes, spleen, and Peyer’s
patches are relatively inactive, thus the germ-free mice are
immune deﬁcient [49].
Another model is the antibiotic-treated mouse model,
where the very eﬀective colonising barrier of conventional
mice is disturbed by adding streptomycin to the drinking
water [50]. Some of the species colonising the gut are
eliminated allowing the new bacteria to colonise. When
administered orally, antibiotics such as ampicillin, clin-
damycin, kanamycin, metronidazole, and streptomycin have
been shown to be useful in this model [51]. Metronidazole
was the least eﬀective antibiotic in decreasing the colonising
barrier, whereas clindamycin was active against anaerobic
bacteria, kanamycin, and streptomycin against facultative
anaerobic bacteria, and ampicillin had a broader range [51].
Hentges et al. found that streptomycin clears oﬀ most of the
Enterobacteriaceae—while the total populations of aerobic
and anaerobic bacteria were not aﬀected [52]. Streptomycin
increased the level of pH in the GI tracts, enhanced the
viscosityofthemucus,makingtheintestinemoresusceptible
to possible infection by pathogenic bacteria [53, 54].
A third model is the human microbiota-associated
rodent (HMA) model where germ-free animals are inocu-
lated with human faecalbacteria, thus mimicking the human
ﬂora composition in the rodent gut [55]. However, it was
shown that changes in the dominant species occasionally
occur following inoculation [56]. The shift in dominant
species composition may be inﬂuenced by the genetic
diﬀerences between humans and mice, but also by the feed
intake. The nutrients present in the GI tract can promote
some bacteria and inhibit others [50]. The dominating strain
in the human sample might not be the same as the one
colonising the animals in high numbers [55, 56].
All GI tract animal models have the advantages of
small diﬀerences in the bacterial ﬂora composition within
the animals due to husbandry standards compared to the
variance within humans and their individual ﬂora [57].
Oneofthemostimportantpointsthatisworthtodiscuss
concerning the assessment between results obtained from
in vitro studies, in vivo diassociated/conventional animal
studies, and extrapolating to humans. The choice of model
inﬂuences the results and should be addressed carefully.
In vitro and in vivo transfer experiments are not com-
parable and do not always provide the same results and4 International Journal of Microbiology
“frequencies”, similarly diﬀerent types of in vivo transfer
experiments are not always comparable. The colonising
barrier and the complexity of the ﬂora in the antibiotic-
treated mice compared to diassociated rats lacking the
colonising barrier (as they were germ free before bacterial
inoculation) can be considered to be a too simple model,
as it does not depict the complexity of the factors involved
in transfer of antibiotic resistance genes in the GI tract.
Transferindiassociatedanimalsonlyprovidestheknowledge
that transfer can occur during colonisation of the GI tract
during less realistic circumstances with no indigenous ﬂora
present and consequently unusually high CFU levels of both
the donor and recipient strains. Diﬀerences in biochemistry,
physiology, and immunology have been observed when
comparingconventionalandgerm-freeanimals[58,59].The
inﬂuence of these factors on the bacteria interactions and
indirectly on the transfer frequency is still unknown. Using
the antibiotic-treated mice model with the conventional
bacterial ﬂora barrier and an intact immune system has the
advantage of mimicking the human GI tract better. However,
adownsideofusingamodelwithacomplexﬂoraisthatgene
transfer might occur to other recipient strains than the spe-
ciﬁc strain which is being investigated, or that the number of
transconjugants is below the detection limit (10CFU/g fae-
ces). The question to be discussed is what is most important
in the development of antibiotic resistance—“one” transfer
event or the level of transconjugants and their spread.
The level of transconjugants as well as their persistence
among the indigenous ﬂora in the GI tract reﬂects the
inﬂuence of the spread and therefore, the antibiotic-treated
model seems to give a reliable answer. Nevertheless, transfer
in vivo cannot be calculated from extrapolations of in vitro
experiments, and humans and animals are diﬀerent both in
ﬂora composition and metabolism [47].
5. LacticAcid Bacteria:IntermediateHosts of
AntibioticResistance Genes?
One quarter of all food production is estimated to involve
microbial fermentation processes by using lactic acid bacte-
rial (LAB) strains [60], for example, sausage, ham, cheese,
and dairy products. In addition, probiotics have become
available on the market, containing a single strain or a
combination of strains. In order to obtain health beneﬁts,
live bacteria around 1011 CFU/mL should be ingested daily
[61]. The proposed problem is that probiotic strains and
starter cultures might contain naturally occurring antibiotic
resistance genes. From a point of safety, it is necessary
to distinguish between intrinsic and acquired resistance
genes and most importantly the transferability of these. The
increasing level of consumption of fermented foods (more
and more products use starter cultures in their production)
and an increasing interest in probiotic products result in
highdailyoccurrencesofantibiotic resistance genesintheGI
tract. The increased level of ingested Gram-positive bacteria
has caused new speculations that these bacteria might also
contribute to the reservoir of antibiotic resistance genes,
and when the right circumstances are present; these genes
could be transferred to the indigenous ﬂora. The worst case
scenario is that antibiotic resistance genes are transferred to
a pathogenic bacterium which could then lead to treatment
failure of an infection. Transfer from LAB strains has been
documented in vitro [62–66], but very few studies have
conﬁrmed this antibiotic resistance transfer in vivo and it
was only observed in the diassociated animal model [62, 64,
66, 67]. Studying the board-host-range conjugative plasmid
pAMβ1,transferwasobserved invitrofromdiﬀerentdonors,
for example, Lactobacillus spp. (L. plantarum, L. reuteri,
L. fermentum, and L. murinus) to other LAB strains [68–
72]. In the diassociated model pAMβ1 has been transferred
from L. reuteri to Enterococcus faecalis [73]a n da m o n g
Lactococcus lactis strains [66], but the transfer among the L.
lactis strain could not be observed in conventional rats [66].
Gram-positive bacteria seem to have a limited inﬂuence on
the spread of antibiotic resistance in the GI tract, despite
the fact that a few multiresistant LAB strains have been
detected in weaning piglets [74]. Nevertheless, conclusive
documentation of transfer in the GI tract from LAB strains is
lacking and therefore more studies need to be carried out.
6. AntibioticResistance Transfer to the
Indigenous Flora in the Gut
The hypothesis that the indigenous ﬂora can become a
reservoir of antibiotic resistance genes remains to this date
neither conﬁrmed nor denied. It is suggested that the Gram-
negative part of the ﬂora has an increased prospect to obtain
antibiotic resistance genes and might act as a reservoir and
transfer the resistance gene further to pathogenic bacteria,
which might lead to infections with limited treatment
possibilities [75]. This is especially true within a hospital
setting, where the antibiotics used are often aimed at the
Gram-negative pathogens, adding selective pressure on the
Gram-negative bacteria. The human microbiota associated
rat model revealed that broad-host range plasmid pAMβ1
can be transferred from L. lactis to indigenous Enterococcus
spp., whereas no transfer was observed to Lactobacillus spp.,
Biﬁdobacterium spp., and Enterobacteriaceae spp. [76]. A
study using voluntary human subjects in 1974 showed that
antibioticresistancetransferoccurredbetweenanEscherichia
coli of animal origin and indigenous E. coli in the GI
tract during tetracycline treatment. Transfer was observed
late in the experiment (36 days after the end of the treat-
ment), but only with the therapeutic levels of tetracycline
(1000mg/daily) administrated and not with the low level of
50mg/day [77]. The observation of “late transfer” has also
been observed in a study using mice, where the indigenous
E. coli transconjugant was observed in high numbers 23 days
after inoculation of the multiresistant Klebsiella pneumoniae
donor [75]. In addition, vancomycin resistance has been
observed to be transferred between Enterococcus spp. in the
GI of humans [78]. Furthermore, the possible transfer of
a plasmid harbouring ampicillin resistance from the food
contaminant Salmonella Enteritidis to indigenous E. coli
in the GI tract of humans was described, and in vitro
experiments conﬁrmed that transfer was possible at high
frequencies [79]. Transfer of any antibiotic resistance genes
is a general concern, yet transfer of Extended spectrumInternational Journal of Microbiology 5
beta-lactamases (ESBL) resistance genes is a category of
its own, which might result in treatment limitations and
in worst cases of treatment failure [4, 80]. Interestingly,
indigenous E. coli strains with a blaCTX−M ESBL gene were
isolated form pigs. During treatment with cephalosporin’s
(veterinary treatment), the diversity of the indigenous E. coli
strains receiving the blaCTX−M genes increased, suggesting
horizontal gene transfer during selective pressure [81]. If
meat for consumption is contaminated with the faecal ESBL
producing E. coli, and if the meat is not properly processed,
humans can ingest the ESBL producing E. coli and the gene
transfer can occur again in the human GI tract. An example
of selective pressure increasing the possibility of transfer
was described by a clinical case documenting transfer of
ACC-1 AmpC (ESBL) from K. pneumoniae to indigenous
E. coli during antibiotic treatment of 1-year old boy [82].
The child was colonised with a K. pneumoniae harbouring
ACC-1 AmpC. The postoperative treatment was imipenem
and amikacin which lead to a spontaneous mutation that
decreased the sensitivity towards imipenem. Subsequently,
the plasmid was transferred to a commensal ampicillin
resistant E. coli during treatment with cefotaxim due to
urinary tract infection caused by the E. coli [82]. This is
a very important case story illustrating and emphasising
the complexity of circumstances and mechanisms during
antibiotic resistance gene transfer in the gut.
7.Farm-to-ForkPerspective
The ecological niches of human, animal, water, and soil
can easily be evaluated as separated small niches, but
this evaluation might not yield the entire truth. Bacteria
are present in microecological niches, but move between
ecosystems from animals to humans, from humans and
animals (faeces and manure) to water and soil and return
to human and animals, through, for example, food (plants
or vegetables). In addition, the use of antibiotic treatment
in each small niche (humans, animals or plants) selects
the resistant strains to become the reservoir of resistance
genes. These antibiotic resistance genes are present and
can be transported within the bacteria from one niche to
another. Figure 1 illustrates the interaction between the
diﬀerent reservoirs of bacteria in the food chain [83]. The
nonpathogenic bacteria are widely used as feed additives of
animal feed, as starter cultures in food preparation, or as
probiotics for humans. Antibiotic treatment of humans (in
thehospitalsorinthecommunity),animals,andpestcontrol
on plants, creates a selection of resistant bacteria in those
areas. Humans ingest meat and plants which might contain
bacteria with antibiotic resistance genes, but the increasing
consumption of fermented food products increases the risk
of antibiotic resistance genes to occur in the intestine. It is
a well-known fact that human foodstuﬀs contain bacteria
harbouring antibiotic resistance genes, but the main focus
has been on pathogen contaminants in foods. Raw food,
which is not properly processed before eating, might result
in infections caused by pathogenic resistant bacterial strains.
Epidemiologically studies have shown that through trace
b a c k ,a no u t b r e a ks t r a i nc a nb er e l a t e dt oas p e c i ﬁ cf o o d
product [84], for example, the presence of multiresistant
Salmonella typhimurium in Carpaccio [85], Shigella sonnei
infections caused by imported baby corn [86], E. coli O157
infections caused by contaminated lettuce [87], and a recent
outbreak caused by Salmonella kedougou [88]. However,
antibiotic resistant pathogenic strains are also frequently
detected in production animals in Europe, such as MRSA
in pigs [89], multiresistant Salmonella infantis in broiler
chicken [90], ESBL producing Salmonella spp. in poultry
[91], and also in food products, such as vancomycin resistant
E.faecalisinturkeymeat[92],multiresistantE.coliinminced
beef[93],andtetracyclineresistantE.faecalisinpoultrymeat
(chicken, turkey and duck), beef, and pork [94].
It has also been demonstrated that antibiotic resistance
genes of diﬀerent Lactic acid bacterial species, for exam-
ple, Lactococcus spp., Streptococcus thermophilus, and Pseu-
domonas spp., are present in “ready to use” products such as
diﬀerent cheese products, raw milk, meat products like pork
chop, turkey, and beef as well as in mushroom and spinach
[95]. In vitro experiments have shown that L. lactis DNA,
containing the tetracycline resistance gene tetS, was success-
fully transformed into the oral cariogenic pathogen Strepto-
coccus mutans [95]. Although this experiment illustrates the
transfer of antibiotic resistant genes from a commensal to a
pathogenic bacterium, these events have not been conﬁrmed
in vivo. Other studies showed transfer of erythromycin
resistance gene ermB from a commensal L. plantarum strain
to E. faecalis in vivo in the diassociated rat model [62].
However, this was not reproducible in the streptomycin-
treated mice model [62]. Although probiotic and industrial
bacterial cultures were seen to possess the acquired antibiotic
resistance genes, no transfer in vitro was observed, neither
intraspecies nor interspecies [96]. Whereas few natural
resistant LAB were isolated from cheese (raw milk without
starter cultures), only two L. lactis strains harbouring the
conjugative tetM resistance transposon Tn916 were able to
transfer to both Lactococcus and Enterococcus [97].
Transfer of antibiotic resistance genes from Gram-
positive to Gram-negative bacteria in vitro is a very rare
event. Inv i t r otransfer of a naturally occurring Gram-
positive plasmid pIP501 in E. faecalis to E. coli has been
described [98]. Another naturally occurring plasmid, pIP823
from Listeria monocytogenes, was only transferred in the
presence of the broad host range plasmid, pAMβ1w h i c h
mobilised the transfer to both E. faecalis and E. coli [99].
Nevertheless, sequence analysis documents almost identical
antibiotic resistance genes and thereby suggests that transfer
occur from Gram-positive to Gram-negative bacteria strains
[29]. In addition, the opposite transfer situation is not
believed to be possible because of the diﬀerence in the gene
expression systems [29].
Plasmid transfer across genus from LAB have been
rarely described and few studies are performed in an in
vivo model like the diassociated rats [62, 73]. The many
in vitro studies showed that the Gram-negative ﬂora
harbours the mobilised plasmids and the main focus
in antibiotic resistance development should remain on
these. Furthermore, transposons like the Tn916 (harboring
tetracycline resistance) were also shown as being transferable6 International Journal of Microbiology
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Figure 1: Schematic representation of the complexity of selection/development of antibiotic resistant bacteria in diﬀerent known reservoirs.
The possible routes of transmission throughout the environment of these resistant bacteria are suggested. The reservoirs where antibiotics
are applied are also suggested as hot spots for horizontal gene transfer. AN: antibiotic treatment/pest control, adapted from [83].
in vitro between Gram-positive and Gram-negative genus
[100]. Studies like this in vitro transfer event should be
further investigated in in vivo models.
Transgenic food has been investigated for its inﬂuence
on the spread of antibiotic resistance, and the conclusion is
that there is very little reason to assume that consumption
of transgenic food or feed additives increases the risk.
Diﬀerent environmental factors have an impact on HGT
events, selective advantage for the bacterial population being
the most important [101].
8. Concluding Remarks
A greatly respected scientist within the antibiotic resistance
area has recently stated that “Evolution of bacteria towards
antibiotic resistance is unavoidable as it represents a
particular aspect of the general evolution of bacteria. Thus,
at the very best, the only hope we can have in the ﬁeld of
antibiotic resistance is to delay dissemination of resistant
bacteria or resistance genes” [29]. In addition, it is suggested
that identifying more resistance mechanisms in antibiotics
producing strains might be the solution to predict the
mechanisms that will be observed in the human pathogenic
strains in the future [29]. However, horizontal gene transfer
does not appear to have homogenised the bacteria. Genetic
diversity and a well-deﬁned phylogenetic tree for bacteria
are still the rule rather than the exception [102].
High level of antibiotic resistance, combined with the
tendency to treat infections with more broad-spectrum
drugs, results in a selection of multiresistant bacteria. Due to
import/exportoffoodproductsandtravellinghabits,asingle
part of the world cannot deal with this threat alone. The
optimal solution would be worldwide consensus on the use
ofantibiotics,bothinhealthcareandintheveterinarysector.
There is no doubt that antibiotic treatment is a necessity,
and the inﬂuence on the total GI ﬂora is a matter of sec-
ondary importance. Conversely, antibiotic treatment creates
a great advantage for resistant bacteria which is selected to
colonisetheintestineandtreatmentmightresultinantibiotic
resistance transfer among Gram-negative bacteria, or to the
indigenous ﬂora or even a pathogen. The ecological eﬀects
of antibiotic treatment on the commensal microﬂora should
be the focus of more studies in the future. Rational use of
antibiotics together with infection control will possibly limitInternational Journal of Microbiology 7
further spread of multiresistant bacteria, but no matter what
boundaries we set up, transfer of antibiotic resistance genes
among bacteria can and will occur.
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